Please login to the form below

Pneumococcal vaccine

This page shows the latest Pneumococcal vaccine news and features for those working in and with pharma, biotech and healthcare.

Merck wins speedy FDA review for 15-valent pneumococcal vaccine

Merck &Co (MSD) has been given a fast-track designation for its next-generation 15-valent pneumococcal conjugate vaccine candidate V114. ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13, although Pfizer is seeking to

Latest news

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

For more than a century, Merck inventors have developed vaccines that help tackle some of society’s biggest public health challenges, and that heritage is reflected today in our pneumococcal vaccine ... Pfizer also announced results from a
Keytruda growth helps Merck to offset COVID-19 impact in Q3

The growth in profits was mainly due to increasing demand for certain drugs, including its blockbuster checkpoint inhibitor Keytruda (pembrolizumab), and its bacterial pneumonia vaccine. ... While sales of its papillomavirus vaccine Gardasil declined due
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck &Co. Pfizer says it could be on course to file for approval of its new generation pneumococcal conjugate vaccine in the US ... Pneumococcal disease is caused by Streptococcus pneumoniae, and
Solid Q1 results lift Pfizer as it waits for pipeline boost

Pfizer’s Prevnar pneumococcal vaccine franchise grew 8% to $1.49bn, around $100m ahead of expectations, although analysts expressed concerns that Pfizer was at risk of falling behind in the race
Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains. Pfizer just got a leg-up in its race with Merck &Co to bring a new-generation pneumococcal vaccine to the US market after ... is in pursuit of PCV-15 (also known as V114), a 15-valent candidate that Merck

More from news
Approximately 1 fully matching, plus 38 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
Deal Watch table for March 2014

26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.
A tailored approach to the BRIC markets

In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in ... Europe. The deal guaranteed GSK a set price and set volumes for the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Principal Medical Writer: Varies on experience

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....